Published

Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.

The mixed serotonin (5-HT) 1A/2A/2B/2C/6/7 receptor agonist psilocybin dose-dependently induces an altered state of consciousness (ASC) that is characterized by changes in sensory perception, mood, thought, and the sense of self. The psychological effects of psilocybin are primarily mediated by 5-HT2A receptor activation. However, accumulating evidence suggests that 5-HT1A or an interaction between 5-HT1A and 5-HT2A receptors may contribute to the overall effects of psilocybin. Therefore, we used a double-blind, counterbalanced, within-subject design to investigate the modulatory effects of the partial 5-HT1A agonist buspirone (20mg p.o.) and the non-hallucinogenic 5-HT2A/1A agonist ergotamine (3mg p.o.) on psilocybin-induced (170 µg/kg p.o.) psychological effects in two groups (n=19, n=17) of healthy human subjects. Psychological effects were assessed using the Altered State of Consciousness (5D-ASC) rating scale. Buspirone significantly reduced the 5D-ASC main scale score for Visionary Restructuralization (VR) (p

Open source BibTeX RIS

Bibliographic context

Journal: European Neuropsychopharmacology
Date: 2016-01-21
Source: Europe PMC
DOI: 10.1016/j.euroneuro.2016.01.005
PubMed: 26875114

Authors

Pokorny T Preller KH Kraehenmann R Vollenweider FX.

Watch author

Topics and keywords

psilocybin Receptor Pharmacology Consciousness Healthy Volunteers Drug Interactions Other Humans Consciousness Disorders Ergotamine Buspirone Hallucinogens Double-Blind Method Female Male Young Adult Serotonin Receptor Agonists Healthy Volunteers Behavior Rating Scale Psilocybin

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.2016-01-21

Related papers

Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression.Journal of Affective Disorders · 2018-03-31 The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography StudyClinicalTrials.gov · 2024-04-18 An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder: A case report.Bipolar Disorders · 2021-05-17 Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosaJournal of Eating Disorders · 2025-05-25 Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions.International Journal of Eating Disorders · 2026-07-01 Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depressionJournal of Affective Disorders · 2026-06-03 Psilocybin and the Development of Serotonin ToxicityThe Primary Care Companion For CNS Disorders · 2024-02-23 Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparationJournal of Affective Disorders · 2023-01-24